P Wheatley-Price1, F Blackhall2, S-M Lee3, C Ma4, L Ashcroft2, M Jitlal5, W Qian6, A Hackshaw5, R Rudd7, R Booton2, S Danson8, P Lorigan2, N Thatcher2, F A Shepherd4. 1. Princess Margaret Hospital/University Health Network, Toronto, Ontario, Canada. Electronic address: pwheatleyprice@toh.on.ca. 2. Christie Hospital, Manchester. 3. University College Hospital, London. 4. Princess Margaret Hospital/University Health Network, Toronto, Ontario, Canada. 5. Cancer Research UK and University College London Cancer Trials Centre, London. 6. Medical Research Council Clinical Trials Unit, London. 7. St Bartholomew's Hospital, London. 8. Weston Park Hospital, Sheffield, UK.
Abstract
BACKGROUND:Some non-small-cell lung cancer (NSCLC) surgical series have indicated that the positive prognostic effect of female sex is limited to patients with adenocarcinoma. We carried out a retrospective analysis to investigate the role of sex and histology on efficacy, toxicity, and dose delivery after chemotherapy. PATIENT AND METHODS: Individual patient data were pooled from five randomized, phase III, advanced NSCLC chemotherapy trials. Primary outcomes were response rate, overall survival (OS), toxicity, and dose delivery. A secondary analysis examined survival by sex in histological subgroups. RESULTS:Of 2349 patients, 34% were women. Women had a higher response rate to chemotherapy (42% versus 40%, P = 0.01) and longer survival than men (median OS 9.6 versus 8.6 months, P = 0.002). The difference in OS remained after adjusting for age, stage, performance status, and histology (hazard ratio 0.83, 95% confidence interval 0.74-0.92, P = 0.0005). Upon further examination, longer survival in women was only seen in patients with adenocarcinoma (test for interaction P = 0.006). There were no differences in hematological toxicity or transfusions. Women experienced more grade 3-4 emesis than men (P < 0.0001) and more dose delays (P = 0.02) or dose reductions (P < 0.0001). CONCLUSION: The positive prognostic effect among women is confirmed in patients receiving platinum-based chemotherapy but appears confined to those with adenocarcinoma histology.
RCT Entities:
BACKGROUND: Some non-small-cell lung cancer (NSCLC) surgical series have indicated that the positive prognostic effect of female sex is limited to patients with adenocarcinoma. We carried out a retrospective analysis to investigate the role of sex and histology on efficacy, toxicity, and dose delivery after chemotherapy. PATIENT AND METHODS: Individual patient data were pooled from five randomized, phase III, advanced NSCLC chemotherapy trials. Primary outcomes were response rate, overall survival (OS), toxicity, and dose delivery. A secondary analysis examined survival by sex in histological subgroups. RESULTS: Of 2349 patients, 34% were women. Women had a higher response rate to chemotherapy (42% versus 40%, P = 0.01) and longer survival than men (median OS 9.6 versus 8.6 months, P = 0.002). The difference in OS remained after adjusting for age, stage, performance status, and histology (hazard ratio 0.83, 95% confidence interval 0.74-0.92, P = 0.0005). Upon further examination, longer survival in women was only seen in patients with adenocarcinoma (test for interaction P = 0.006). There were no differences in hematological toxicity or transfusions. Women experienced more grade 3-4 emesis than men (P < 0.0001) and more dose delays (P = 0.02) or dose reductions (P < 0.0001). CONCLUSION: The positive prognostic effect among women is confirmed in patients receiving platinum-based chemotherapy but appears confined to those with adenocarcinoma histology.
Authors: Corey J Langer; Shirish M Gadgeel; Hossein Borghaei; Vassiliki A Papadimitrakopoulou; Amita Patnaik; Steven F Powell; Ryan D Gentzler; Renato G Martins; James P Stevenson; Shadia I Jalal; Amit Panwalkar; James Chih-Hsin Yang; Matthew Gubens; Lecia V Sequist; Mark M Awad; Joseph Fiore; Yang Ge; Harry Raftopoulos; Leena Gandhi Journal: Lancet Oncol Date: 2016-10-10 Impact factor: 41.316
Authors: María J Pajares; Jackeline Agorreta; Marta Larrayoz; Aurélien Vesin; Teresa Ezponda; Isabel Zudaire; Wenceslao Torre; María D Lozano; Elisabeth Brambilla; Christian Brambilla; Ignacio I Wistuba; Carmen Behrens; Jean-Francois Timsit; Ruben Pio; John K Field; Luis M Montuenga Journal: J Clin Oncol Date: 2012-02-21 Impact factor: 44.544
Authors: Winson Y Cheung; Qian Shi; Michael O'Connell; James Cassidy; Charles D Blanke; David J Kerr; Jeff Meyers; Eric Van Cutsem; Steven R Alberts; Greg Yothers; Daniel J Sargent Journal: Clin Colorectal Cancer Date: 2013-06-27 Impact factor: 4.481
Authors: Matthew R Trendowski; Omar El Charif; Paul C Dinh; Lois B Travis; M Eileen Dolan Journal: Clin Cancer Res Date: 2018-10-10 Impact factor: 12.531
Authors: J Remon; E Molina-Montes; M Majem; P Lianes; D Isla; P Garrido; E Felip; N Viñolas; J de Castro; A Artal; M-J Sánchez Journal: Clin Transl Oncol Date: 2013-11-26 Impact factor: 3.405